Riffyn Highlighted in Forbes - Five Things Big Pharma — and Its Investors — Could Learn from Synthetic Biology
Riffyn got its start in the synthetic biology space. It even landed its first major customer (Novozymes) at a SynBioBeta conference. Recently, SynBioBeta’s CEO John Cumbers caught up with Tim about Riffyn on his Forbes column in a piece entitled “Five Things Big Pharma -- and Its Investors -- Could Learn from Synthetic Biology.” In the article Cumbers asks Riffyn CEO, Tim Gardner, what he thinks are five lessons he’s learned in synthetic biology and biomanufacturing that biopharma should hear. Curious to know what he said? Read the article on Forbes.
Embriette is an academic-turned science writer with a passion for spreading responsible science. She holds a PhD in microbiome research from Baylor College of Medicine. After a 4-year post-doc, during which she managed the world's largest citizen science research project (the American Gut Project), Embriette became a full-time science writer and research consultant. You can find her work at riffyn.com, synbiobeta.com, and her personal webpage: drhydenotjekyll.com